Certain IBD biologics tied to poor immune response to COVID-19 vaccine
Perhaps patients should be tested for humoral immunity to guide personal scheduling of boosters, the researchers suggest
Patients on infliximab or tofacitinib for inflammatory bowel disease have weaker immune responses to COVID-19 vaccines and should be prioritized for booster shots, UK clinicians warn.
The magnitude of reduction in antibody response following a primary course of vaccination was particularly striking in those treated with the anti-TNF therapy, results from their prospective case-control study suggest.
